Blog
RSS FeedPosted by Michael Wonder on 12 Jun 2019
New drug helps extend survival rate of men with advanced prostate cancer: B.C. Cancer Agency study
10 June 2019 - At two years, advanced prostate cancer patients taking the trial drug, in addition to their standard treatment, ...
Posted by Michael Wonder on 06 Jun 2019
Patients, physicians raise concerns with BC biosimilar non-medical switching policy
6 June 2019 - On 27 May, the Government of British Columbia announced a policy that will forcibly switch thousands ...
Posted by Michael Wonder on 28 May 2019
Canadian Biosimilars Forum applauds B.C. Government's landmark decision to enhance adoption of biosimilars and calls on remaining provinces to follow
27 May 2019 - The Canadian Biosimilars Forum today commends the Government of British Columbia for taking a decisive step ...
Posted by Michael Wonder on 28 May 2019
BC PharmaCare’s Biosimilars Initiative an important step towards improving patient access to safe and effective medicines
27 May 2019 - Biosimilars Initiative implementation could contribute to significant cost savings for the BC health care system. ...
Posted by Michael Wonder on 27 May 2019
B.C. becomes first province to force change to biosimilar drugs
27 May 2019 - The change will save the government nearly $100 million over the next three years. ...
Posted by Michael Wonder on 11 Dec 2018
Glatect added to public drug plan in British Columbia as sole RRMS treatment of its type
11 December 2018 - Pendopharm’s Glatect (glatiramer acetate) — a treatment for patients with relapsing-remitting multiple sclerosis — has been added ...
Posted by Michael Wonder on 30 Aug 2018
Renflexis (infliximab for injection) added to British Columbia's Provincial Drug Plan for all approved indications
22 August 2018 - Renflexis has been added to drug formulary for the treatment of adult and paediatric Crohn's disease and ...
Posted by Michael Wonder on 29 Aug 2018
B.C. to sue opioid makers for health care expenses of overdose crisis
29 August 2018 - The British Columbia Government will sue opioid manufacturers including Purdue Pharma in an effort to recoup ...
Posted by Michael Wonder on 24 Jul 2018
Cystic fibrosis patients launch class-action suit over access to costly drug
24 July 2018 - A young Victoria woman with cystic fibrosis who fought to get coverage of a life-changing drug ...
Posted by Michael Wonder on 05 Jul 2018
B.C. charity fights feds for access to life-saving medicine
5 July 2018 - Cure SMA Canada is urging the federal government to reimburse the costs of Spinraza. ...
Posted by Michael Wonder on 09 May 2018
B.C., where access to a wait-list is considered access to health care
8 May 2018 - Last month, the British Columbia government decided to get tough with private health-care clinics, announcing that ...
Posted by Michael Wonder on 16 Nov 2017
British Columbia and Prince Edward Island become the first provinces to add Erelzi (etanercept) to public drug plans for the treatment of multiple inflammatory diseases
16 November 2017 - Erelzi also becomes the first biosimilar indicated for polyarticular juvenile idiopathic arthritis under these provincial public drug ...
Posted by Michael Wonder on 10 May 2017
Provincial drug plans, including Ontario and BC, make Entyvio (vedolizumab) available to treat inflammatory bowel disease
9 May 2017 - Gut-selective treatment now funded publicly for Canadians with ulcerative colitis and Crohn's disease. ...
Posted by Michael Wonder on 24 Mar 2017
Hope of B.C. coverage for life-saving cystic fibrosis drug dashed
23 March 2017 - 'It's about dollars,' says father of 16-year-old who claims son's life was changed by access to the ...
Posted by Michael Wonder on 23 Mar 2017
British Columbia lists Epclusa on public drug plan to treat all six genotypes of chronic hepatitis C infection
21 March 2017 - British Columbia also broadens access for patients with less advanced disease who have other health conditions. ...